CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Stanford University |
Dr. Alfred T Lane |
Disease Team Research I |
iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Stanford University |
Professor Irving L Weissman MD |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| University of California, Los Angeles |
Dr. Dennis J Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| City of Hope, Beckman Research Institute |
Prof. John A. Zaia |
Disease Team Research I |
ZINC FINGER NUCLEASE-BASED STEM CELL THERAPY FOR AIDS |
$14,536,969 |
| University of Southern California |
Mark Salman Humayun |
Disease Team Research I |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$18,904,916 |
| University of California, San Diego |
Dr. Dennis A Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
| University of California, San Diego |
Dr. Gene Wei-Ming Yeo |
Basic Biology I |
RNA Binding Protein-mediated Post-transcriptional Networks Regulating HPSC Pluripotency |
$1,308,901 |
| University of California, San Diego |
Karl H. Willert |
Basic Biology I |
WNT signaling and the control of cell fate decisions in human pluripotent stem cells. |
$1,329,298 |
| University of California, Davis |
Dr. Min Zhao |
Basic Biology I |
Directing migration of human stem cells with electric fields |
$816,228 |
| University of California, Los Angeles |
Dr. Michael A. Teitell |
Basic Biology I |
Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| University of Southern California |
Dr. Martin Pera |
Basic Biology I |
The stem cell microenvironment in the maintenance of pluripotency and reprogramming |
$1,325,723 |
| Stanford University |
Dr. Julien Sage |
Basic Biology I |
The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Stanford University |
Dr. Susan K McConnell |
Basic Biology I |
Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| University of California, Los Angeles |
Bennett G Novitch |
Basic Biology I |
Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| University of California, Los Angeles |
Dr. Robb Maclellan Dr. |
Basic Biology I |
Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| University of Southern California |
Dr. Wange Lu |
Basic Biology I |
Defining the molecular mechanisms of somatic cell reprogramming |
$1,365,580 |
| Stanford University |
Professor Helen M. Blau PhD |
Basic Biology I |
Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| University of California, Los Angeles |
Dr. Luisa Iruela-Arispe |
Basic Biology I |
Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| Scribe Therapeutics |
Maria Mirotsou |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Dr Melissa Calton |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,916,702 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,350,596 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,499,999 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
| Community Health System |
Haifaa Abdulhaq |
CCCE Grant |
Establishing a CIRM Community Care Center of Excellence in the Central Valley |
$8,996,101 |
| Lundquist Institute for Biomedical Innovation at Harbor – UCLA Medical Center |
Christina Wang |
CCCE Grant |
South Los Angeles Community Center of Excellence for Regenerative Medicine |
$9,000,000 |
| University of California, San Diego |
Jonathan Sebat |
ReMIND – Discovery Stage ReMIND |
Modeling the genetic basis of psychopathology in schizophrenia and autism |
$12,703,708 |
| University of California, San Francisco |
Mercedes Paredes |
ReMIND – Discovery Stage ReMIND |
Multi-gene modulation to rescue CNS-associated microdeletion syndromes |
$6,253,897 |
| University of California, Los Angeles |
Aparna Bhaduri |
ReMIND – Discovery Stage ReMIND |
Defining Neurovascular Metabolism in Neurodevelopmental and Neuropsychiatric Disorders |
$10,330,000 |
| University of California, San Francisco |
Tomasz Nowakowski |
ReMIND – Discovery Stage ReMIND |
CIRM Center for Neuropsychiatric Stem Cell Proteomics |
$13,781,522 |
| Scripps Research Institute |
Xin Jin |
ReMIND – Discovery Stage ReMIND |
Translational epigenomics: dissecting cell type-specific function of neuropsychiatric risk genes in vivo |
$11,376,314 |
| Scripps Research Institute |
Stuart A Lipton |
ReMIND – Discovery Stage ReMIND |
Multiomic Studies of Idiopathic Intellectual Disability and Autism Spectrum Disorder (ID/ASD) |
$17,365,387 |
| University of California, San Francisco |
Alex Pollen |
ReMIND – Discovery Stage ReMIND |
Deep phenotyping of human brain organoid models of autism spectrum disorder to unravel disease heterogeneity and develop biomarkers and treatments |
$12,297,272 |
| Coast to Coast Conferences & Events |
Calli France |
Conference – 2026 CIRM Trainee Network Conference |
2025 CIRM Trainee Networking Conference |
$413,145 |
| University of Southern California |
Dr. Francesca Mariani |
Conference – 2026 CIRM Trainee Network Conference |
Manage the 2024 CIRM Annual Trainee Network Conference |
$348,626 |
| EVERSANA |
Ms. Liana Rostamian |
Patient Support Program |
Patient Support Program to Improve Accessibility to Eligible CIRM-Trial Patients |
$2,485,000 |
| Gladstone Institutes, J. David |
Dr. Bruce R. Conklin |
Shared Labs Grant – Enhancing/Expanding SRLs |
A Center for Stem Cell Disease Modeling and Therapeutics |
$3,999,997 |
| Cedars-Sinai Medical Center |
Arun Sharma |
Shared Labs Grant – Enhancing/Expanding SRLs |
Shared Resource Laboratory for Advanced Stem Cell-Based Modeling |
$3,991,879 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg Dr. |
Shared Labs Grant – Enhancing/Expanding SRLs |
Shared Resources Laboratory for Stem Cell-Based Modeling in Stem Cell Biology and Engineering |
$3,999,995 |
| Salk Institute for Biological Studies |
Dr. Fred H Gage |
Shared Labs Grant – Enhancing/Expanding SRLs |
Shared Resource Laboratory for Stem Cell-Based Modeling: Resources for Exploring the Biological Underpinnings of Aging and Age-Associated Pathologies |
$3,641,064 |
| University of Southern California |
Dr. Nils O. Lindstrom |
Shared Labs Grant – Enhancing/Expanding SRLs |
CIRM ASCEND Center – Advancing Stem Cell Education and Novel Discoveries |
$3,663,163 |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
Shared Labs Grant – Enhancing/Expanding SRLs |
A modular automation approach to stem cell modeling to increase throughput, reproducibility and access |
$3,999,999 |
| University of California, Irvine |
Craig Michael Walsh |
Shared Labs Grant – Enhancing/Expanding SRLs |
Shared Resources Laboratories to Enhance In Vitro Stem Cell Modeling and Training |
$3,641,396 |